Pegvisomant is currently the only GH-receptor antagonist approved by the U.S. Food and Drug Administration that is available for treatment of acromegaly, and it is a pegylated analog of human GH, which directly competes for receptor binding with plasma GH (37). Here, GH1 is linked to acromegaly.